Targeted Radiotherapies: A New Approach to Treating Cancer
BOSTON, MA, February 27, 2025 /24-7PressRelease/ — ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers, announced today that its CEO, Chris Adams, will chair a session at the targeted therapy conference in Boston. The conference will include attendees from industry experts to patient groups.
The Target Selection and Drug Design Conference will take place on the 25th-27th February 2025 in Boston, MA. This event will explore advances in radiobiological, radiodecay and radiation absorption mechanisms to inform optimal targeting strategies from small molecules, peptide, nanobodies, antibody fragments as well as linker and chelator technologies for enhanced PK. Bringing it all together, gain a commercial perspective to enhance your strategic decision-making in target selection and novel drug rationale within this highly dynamic field.
Incorporating key insights from radiopharmaceuticals’ leading drug discovery minds from medicinal chemistry, radiobiology, biology, discovery, R&D, pharmacology, computational biology, commercial strategy and many more, this is the only global opportunity to gain practical insights into your approaches, from target selection to drug design.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer, developing both the imaging agents that can identify appropriate patients, as well as the targeted therapies for these patients. The company’s products have progressed through early clinical development. The Andarix technology is based on a proprietary somatostatin peptide conjugate applicable to lung, pancreatic, neuroendocrine, and other cancers. Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung, neuroendocrine, and pancreatic tumors. To learn more about Andarix, please visit www.andarix.com.
—
For the original version of this press release, please visit 24-7PressRelease.com here
